BRITISH DRAGON

Pharmaceuticals

  • Blue Tier

Tesa 20

TESAMORELIN (20 mg Vial) Dosage Protocol

Vial by kaco6446 on Sketchfab

Tesamorelin (20 mg Vial) Dosage Protocol

Table of Contents

  • Quickstart Highlights

Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH)[1]. It stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits[2]. Tesamorelin is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy and is studied for metabolic disorders and aging research[3][4].

  • Reconstitute: Add 3.0 mL bacteriostatic water per 20 mg vial → ~6.67 mg/mL concentration.
  • Standard daily dose: 2 mg (2000 mcg) once daily subcutaneously (FDA-approved protocol).
  • Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); reconstituted: refrigerate and use within 7 days with bacteriostatic water.

  • Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing

Standard FDA-Approved Protocol (3.0 mL = ~6.67 mg/mL)

WeekDaily Dose (mg / mcg)Units (per injection) (mL)
Week 11 mg / 1000 mcg15 units (0.15 mL)
Weeks 2–12+2 mg / 2000 mcg30 units (0.30 mL)

Frequency: Inject once daily subcutaneously, preferably in the evening to coincide with nocturnal GH release[5][6]. The 2 mg daily dose is the standard FDA-approved regimen for HIV lipodystrophy[7][8]. A one-week titration at 1 mg may improve tolerability before advancing to the full 2 mg dose.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 7 days when reconstituted with bacteriostatic water[1].

Important: This guide is for educational purposes only and is not medical advice.

  • Supplies Needed

Plan based on an 8–16 week daily protocol at the standard 2 mg dose (after Week 1 titration).

  • Peptide Vials (Tesamorelin, 20 mg each):

     

    • 8 weeks ≈ 6 vials (105 mg total)
    • 12 weeks ≈ 9 vials (161 mg total)
    • 16 weeks ≈ 11 vials (217 mg total)
  • Insulin Syringes (U-100, 1 mL capacity):

     

    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

     

    • 8 weeks (6 vials): 18 mL → 2 × 10 mL bottles
    • 12 weeks (9 vials): 27 mL → 3 × 10 mL bottles
    • 16 weeks (11 vials): 33 mL → 4 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

     

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100-count boxes

  • Protocol Overview

Concise summary of the once-weekly regimen.
  • Goal: Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation[3][4].
  • Schedule: Daily subcutaneous injections for 12–26 weeks (extendable to 52 weeks with medical supervision)[3].
  • Dose: 2 mg (2000 mcg) daily after Week 1 titration.
  • Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate measurement.
  • Storage: Lyophilized refrigerated; reconstituted refrigerated up to 7 days; avoid freeze-thaw.

  • Dosing Protocol

Suggested weekly titration approach from clinical trials.

FDA-approved daily dosing approach with tolerability titration.

  • Week 1: 1 mg (1000 mcg) once daily to assess tolerability.
  • Weeks 2+: 2 mg (2000 mcg) once daily (standard FDA-approved dose)[7][8].
  • Frequency: Once per day (subcutaneous), preferably in the evening.
  • Cycle Length: 12–26 weeks; clinical trials support up to 52 weeks with monitoring[3].
  • Timing: Evening administration recommended; rotate injection sites.

  • Storage Instructions

Proper storage preserves peptide quality and stability.
  • Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) stable at 20–25 °C (68–77 °F) before reconstitution[1].
  • Reconstituted (with bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days[1].
  • Reconstituted (with sterile water): Use immediately; discard any unused portion[1].
  • Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.

  • Important Notes

Practical considerations for consistency and safety.
  • Use new sterile insulin syringes for each injection; dispose in a sharps container[10].
  • Rotate injection sites (abdomen at least 2 inches from navel, thighs, upper arms) to reduce local irritation[6][10].
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Monitor IGF-1 levels periodically due to potent GH stimulation; observe blood glucose in diabetic patients[9].
  • Document daily dose and site rotation to maintain consistency.

  • How This Works

Tesamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation[2]. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6–12 months[3][4]. Research also explores tesamorelin’s potential to reduce liver fat in NAFLD patients and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines[4].

  • Potential Benefits & Side Effects

Observations from Phase 2 human clinical trials.

Potential Benefits:

  • Significant reduction in visceral adipose tissue (measurable after 3–6 months)[3].
  • Improved lipid profiles and potential liver fat reduction in NAFLD[4].
  • Enhanced cognitive function in older adults (research ongoing)[4].
  • Well-tolerated with maintained benefits during continuous use up to 52 weeks[3].

Common Side Effects:

  • Injection-site reactions: Mild redness, itching, pain, or bruising at injection area[9].
  • Musculoskeletal symptoms: Joint pain (arthralgia), muscle aches, peripheral edema (mild swelling)[9].
  • Carpal tunnel symptoms: Occasional tingling or numbness in extremities (dose-dependent, reversible).
  • Metabolic monitoring: IGF-1 elevation requires monitoring; small increases in HbA1c observed in some patients[9].

Contraindications:

  • Active malignancies (tesamorelin may accelerate growth of latent tumors)[9].
  • Pregnancy (may harm fetus)[9].
  • Known hypersensitivity to tesamorelin or mannitol[9].

  • Lifestyle Factors

Complementary strategies for optimal metabolic outcomes.
  • Combine with a balanced, protein-forward diet to support GH/IGF-1 anabolic effects.
  • Integrate resistance training and aerobic activity to maximize fat loss and metabolic benefits.
  • Prioritize 7–9 hours of quality sleep to optimize natural GH pulsatility.
  • Manage stress through mindfulness or relaxation techniques to support adherence and recovery.

  • Injection Technique

Subcutaneous injection best practices from clinical guidelines[10].

  • Clean the vial stopper and skin with alcohol swabs; allow to air-dry completely.
  • Pinch a skinfold at the injection site (abdomen preferred, at least 2 inches from navel)[6].
  • Insert the needle at 90° (if adequate subcutaneous fat) or 45° (if lean)[10].
  • Release the pinch, then inject slowly; wait 2–3 seconds before withdrawing.
  • Rotate injection sites systematically (left/right abdomen, thighs, upper arms) to prevent lipohypertrophy[6].
  • Dispose of used syringes immediately in a puncture-proof sharps container[10].

  • Video

  • Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Tesamorelin is a prescription medication (FDA-approved as Egrifta®) for HIV-related lipodystrophy. Any off-label use should comply with applicable laws and be conducted under appropriate medical supervision. Consult a qualified medical professional before considering any therapeutic use of tesamorelin.

References

  • Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
— National Institutes of Health, NIDDK (2018)
View Source
  • Tesamorelin (Subcutaneous route) – Drug Information

— Mayo Clinic / IBM Merative (2025)

View Source
  • Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials
— J. Clin. Endocrinol. Metab. (2010)
View Source
  • Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: A randomized, placebo-controlled trial
— PLoS ONE (2017)
View Source
  • Tesamorelin can improve cognitive function (Research Highlight)
— Nature Reviews Endocrinology (2012)
View Source
  • Tesamorelin Injection – MedlinePlus Drug Information
— MedlinePlus (U.S. National Library of Medicine) (2025)
View Source
  • EGRIFTA SV (tesamorelin) – Full Prescribing Information
— Theratechnologies, Inc. (FDA Label) (2024)
View Source
  • Tesamorelin: Uses, Dosage, Side Effects, Warnings
— Drugs.com (AHFS Monograph & Patient Info) (2025)
View Source
  • Tesamorelin – LiverTox (Safety Profile)

— NIH NIDDK LiverTox Database (2018)

View Source
  • Administration of Parenteral Medications – Nursing Skills (Open RN Textbook)
— Open RN, Chippewa Valley Technical College (2023)
View Source
  • British Dragon Pharmaceuticals
— Quality and batch documentation for research-grade tesamorelin
View Source
  • Video

Mechanism Breakdown — 3rd Party Analysis

This video provides an external overview on Tesamorelin.

External Source
  • Dosing protocol

Titration schedule.

Standard research titration model. Adjust under qualified clinical observation only. Not for human therapeutic use.

Phase 01

Wk 1 — 4

1 mg (15units)

Once night daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

1 mg (15units)

Once night daily

Standard titration step

Phase 03

Wk 9 — 12

1 mg (15 units)

Once night daily

Maintenance evaluation

Phase 04

Wk 13+

2 mg (30 units)

Once night daily

Optional research extension

  • Clinical Notice

Research use only.

TESA 20 is supplied strictly for in-vitro laboratory research and biochemical analysis. It is not intended for human consumption, diagnostic use, veterinary application or therapeutic administration of any kind.

Handling must be performed by qualified personnel in compliance with applicable institutional and jurisdictional safety standards. The information contained on this protocol sheet is provided for educational and reference purposes only and does not constitute medical advice.
  • Not for human use
  • Store at 2–8 °C, protected from light
  • Reconstitute under aseptic conditions
  • Document all research observations
 

Blue Tier Catalogue

Explore the full British Dragon research line.

Premium-tier compounds engineered for serious metabolic, longevity and performance research programs.
View Products
Back to Top